Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario

被引：0
|
作者：
Iacono, D. [1 ]
Vitale, M. G. [2 ]
Cortiula, F. [2 ]
Cinausero, M. [2 ]
Tullio, A. [3 ]
Valent, F. [3 ]
Macerelli, M. [1 ]
Follador, A. [1 ]
Vogrig, A. [4 ]
Minisini, A. M. [1 ]
Puglisi, F. [2 ]
Fasola, G. [1 ]
机构：
[1] ASUIUD Santa Maria Misericordia, Dept Oncol, Udine, Italy
[2] Univ Udine, Dept Med DAME, Udine, Italy
[3] ASUIUD Santa Maria Misericordia, Hyg & Clin Epidemiol Unit, Udine, Italy
[4] ASUIUD Santa Maria Misericordia, Dept Neurosci, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1198P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Predictors for the Development of Neurological Immune-Related Adverse Events of Immune Checkpoint Inhibitors and Impact on Mortality
    Yan, Chen
    Huang, Merry
    Swetlik, Carol
    Toljan, Karlo
    Bena, James
    Funchain, Pauline
    McGinley, Marisa
    NEUROLOGY, 2022, 99 (23) : S26 - S26
  • [32] Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
    Albandar, Heidar J.
    Fuqua, Jacob
    Albandar, Jasim M.
    Safi, Salahuddin
    Merrill, Samuel A.
    Ma, Patrick C.
    CANCERS, 2021, 13 (05) : 1 - 15
  • [33] The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
    Xiao-Hui Jia
    Lu-Ying Geng
    Pan-Pan Jiang
    Hong Xu
    Ke-Jun Nan
    Yu Yao
    Li-Li Jiang
    Hong Sun
    Tian-Jie Qin
    Hui Guo
    Journal of Experimental & Clinical Cancer Research, 39
  • [34] Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
    Jain, P.
    Bugarin, J. Gutierrez
    Guha, A.
    Jain, C.
    Patil, N.
    Shen, T.
    Stanevich, I.
    Nikore, V.
    Margolin, K.
    Ernstoff, M.
    Velcheti, V.
    Barnholtz-Sloan, J.
    Dowlati, A.
    ESMO OPEN, 2021, 6 (05)
  • [35] The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
    Jia, Xiao-Hui
    Geng, Lu-Ying
    Jiang, Pan-Pan
    Xu, Hong
    Nan, Ke-Jun
    Yao, Yu
    Jiang, Li-Li
    Sun, Hong
    Qin, Tian-Jie
    Guo, Hui
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [36] Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence
    Xu, Huiru
    Feng, Huijing
    Zhang, Weihong
    Wei, Feng
    Zhou, Li
    Liu, Liang
    Zhao, Yu
    Lv, Yingge
    Shi, Xiuhuan
    Zhang, Junping
    Ren, Xiubao
    EXPERIMENTAL CELL RESEARCH, 2022, 416 (01)
  • [37] Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: A monocentric real-world observational study
    Ge, Xiaoxiao
    Jiang, Weiping
    Li, Hongqing
    Wu, Yanxu
    Li, Xiangyang
    Cui, Shaohua
    CANCER MEDICINE, 2023, 12 (18): : 18491 - 18502
  • [38] Real-world data in the era of immune checkpoint inhibitors
    Narita, Yukiya
    ANNALS OF ONCOLOGY, 2021, 32 : S250 - S250
  • [39] Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
    Wang, Feicheng
    Yang, Shihao
    Palmer, Nathan
    Fox, Kathe
    Kohane, Isaac S.
    Liao, Katherine P.
    Yu, Kun-Hsing
    Kou, S. C.
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [40] Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
    Feicheng Wang
    Shihao Yang
    Nathan Palmer
    Kathe Fox
    Isaac S. Kohane
    Katherine P. Liao
    Kun-Hsing Yu
    S. C. Kou
    npj Precision Oncology, 5
12345